Discovery of new mediators for cerebral infarction stem cell therapy

[뉴스토마토 동지훈 기자] A new mediator in the treatment of cerebral infarction using stem cells was discovered by Korean medical staff.

Korea University Anam Hospital announced on the 28th that a team led by Professor Donghyuk Park of Neurosurgery has discovered a new mediator of stem cell therapy in the treatment of ischemic stroke (cerebral infarction).

Stroke is considered as one of the most important socio-economic diseases due to the rapid aging of the population worldwide. It also ranked third in mortality in 2019 after cancer and heart disease. Ischemic stroke is a disease requiring regenerative medicine in chronic stroke because there is no appropriate treatment method except for patients who can use thrombolytic drugs or mechanical thrombus removal in the acute stage.

Through these studies, Professor Donghyuk Park’s team is showing results of research on regenerative treatment using stem cells, such as suggesting the possibility of ischemic stroke treatment by intravenous stem cell administration and announcing the results of doubling the therapeutic effect.

Recently, Professor Donghyuk Park’s team, together with Professor Sangwon Lee of the Department of Chemistry at Korea University, administered adipose-derived mesenchymal stem cells intravenously to animals with cerebral infarction and analyzed the cerebrospinal fluid extracted from the brains of animals with cerebral infarction. protein factors were discovered.

This protein factor is a substance called ’14-3-3 theta’, ‘MAG’, and ‘neurocan’. Professor Park Dong-hyuk’s team is being evaluated for discovering a new mediator that causes the therapeutic effect of mesenchymal stem cells in the treatment of cerebral infarction through this study.

This research was published in the recent issue of Cell Transplantation, an international academic journal in the field of regenerative medicine.

Prior to the presentation of this study, Professor Donghyuk Park’s team announced the results of a study that said that if a hypertonic solution called mannitol is administered intravenously before intravenous administration of adipose-derived mesenchymal stem cells in animals with cerebral infarction, the effect of stem cells in treating cerebral infarction is doubled. there is a bar

This study is expected to be an important clinical foundation that can dramatically increase the treatment effect of cerebral infarction when it is approved to use a stem cell treatment for cerebral infarction patients in actual clinical practice.

By Dong Ji-hoon, staff reporter [email protected]

ⓒ Delicious News Tomato, reprinted without permission – redistribution prohibited


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.